Sun paper: the subsidiary plans to acquire 100% equity of Liujing Chengquan with 1.5 billion yuan

Synthetic Biology: Who Will Emerge as the Winner?

The 21st century is the century of biology. Synthetic biology is believed to be a ‘World Changing’ industry. But the potential risks like cost control and commercialization pathways are fatefully tied to the ups and downs of countless investment decisions and the destiny of the many new start-ups getting involved. We look forward to seeing an emerging ‘giant’ on the horizon of this exciting industry.

Semiconductor Company iSABers materials Completes Over $220 Million Series A++ Financing

iSABers materials (Chinese: 青禾晶元), a semiconductor materials bonding and integration technology company, announced that it has completed a Series A++ financing round totaling RMB 220 million.

CNMPA Approved World's First Inhaled COVID-19 Vaccine Mist

The liquid form of the vaccine is changed into an aerosol using a nebulizer. It can then be inhaled through the mouth using the nebulizer machine. According to CanSino, the vaccine can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath.

China Speed: Two COVID-19 Vaccines Recognized by WHO

As the second blow of the pandemic comes near the sight, China's newly-developed vaccines have been approved by the World Health Organization and available at an affordable price.

Bloomage: Injecting Biotechnology into Beauty Care

Listed on the Chinese Star Market in November 2019, Bloomage was trading at CNY 138.01 as of June 24, 2020, over 38% higher than the IPO price of CNY 100.